Methods for treating pain by administering peptides derived from human basic proline-rich lacrimal protein

Patent metadata

Field	Value
Publication number	US-9403871-B2
Application number	US-201414281018-A
Country	US
Kind code	B2
Filing date	May 19, 2014
Priority date	Mar 19, 2004
Publication date	Aug 2, 2016
Grant date	Aug 2, 2016

Abstract

The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.

First claim

The invention claimed is:

1. A method for treating pain comprising administering an effective amount of an isolated peptide consisting of up to 15 amino acids to a human subject,
wherein the peptide comprises the sequence Glu-Arg-Phe-Ser-Arg (SEQ ID NO: 3) or Glp-Arg-Phe-Ser-Arg (SEQ ID NO: 7),
wherein the peptide exhibits an inhibitory property against a neutral endopeptidase or an aminopeptidase and
wherein the peptide has the same amino acid sequence as that found within human Basic Proline-rich Lacrimal Protein (SEQ ID NO:2) or differs from the amino acid sequence found within SEQ ID NO:2 by two or less amino acid substitutions.

2. The method of claim 1 , wherein the peptide comprises the sequence Glu-Arg-Phe-Ser-Arg (SEQ ID NO: 3).

3. The method of claim 1 , wherein the peptide consists of the sequence Glu-Arg-Phe-Ser-Arg (SEQ ID NO: 3).

4. The method of claim 1 , wherein the peptide comprises the sequence Glp-Arg-Phe-Ser-Arg (SEQ ID NO: 7).

5. The method of claim 1 , wherein the peptide consists of the sequence Glp-Arg-Phe-Ser-Arg (SEQ ID NO: 7).

6. The method of claim 1 , comprising administering a dose of 10-100 mg of the peptide.

7. The method of claim 2 , comprising administering a dose of 10-100 mg of the peptide.

8. The method of claim 3 , comprising administering a dose of 10-100 mg of the peptide.

9. The method of claim 4 , comprising administering a dose of 10-100 mg of the peptide.

10. The method of claim 5 , comprising administering a dose of 10-100 mg of the peptide.

11. The method of claim 1 , wherein the isolated peptide is less than 10 amino acids.

12. The method of claim 2 , wherein the isolated peptide is less than 10 amino acids.

13. The method of claim 4 , wherein the isolated peptide is less than 10 amino acids.

14. The method of claim 6 , wherein the isolated peptide is less than 10 amino acids.

15. The method of claim 7 , wherein the isolated peptide is less than 10 amino acids.

16. The method of claim 9 , wherein the isolated peptide is less than 10 amino acids.

Assignees

• Pasteur Institut

Inventors

• Rougeot Catherine
• Huaulme Jean-Francois
• Ungeheuer Marie-Noelle
• Wisner Anne
• Dufour Evelyne

Classifications

• A61P5/22

  for decreasing, blocking or antagonising the activity of calcitonin · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P5/20

  for decreasing, blocking or antagonising the activity of PTH · CPC title